Warrants of series TO6 were exercised to approximately 44.8 percent and Prolight Diagnostics receives approximately SEK 9.8 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Prolight Diagnostics publishes quarterly report Q1, 2024
Financial overview First quarter, January 1 – March 31, Q1 2024 Group(figures in parentheses refer to the corresponding period in the previous year) Net sales amounted to 0 (0). Other operating income amounted to SEK 68 (39) thousand. The profit after tax amounted to SEK -8,929 (-7,580) thousand. Earnings per share before and after dilution: […]
Prolight announces positive accounting adjustments for the full year 2023
Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, announced today that the company’s 2023 year-end release contains an understated claim on the UK tax authority related to research and development. The revised estimate of Prolight’s claim is approximately SEK 5.6 million higher than previously reported. In the annual report for 2023, which will be […]
Prolight Diagnostics publishes year-end report 2023
Financial overview Fourth quarter, 1 October – 31 December, Q4 2023 Group(figures in the brackets refer to the corresponding period in previous year) • Net sales amounted to 0 (0).• Other operating income amounted to kSEK 5,941 (2,051).• The profit after tax amounted to kSEK -2,382 (-2,809).• Earnings per share before and after dillution: SEK […]
Prolight’s Board of Directors have decided to carry out a directed issue of units to underwriters in connection with the completed rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Prolight announces outcome in the rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Prolight Diagnostics publishes quarterly report Q3, 2023
Financial overviewThird quarter, 1 July – 30 September, Q3 2023 Group (figures in the brackets refer to the corresponding period in previous year) Net sales amounted to 0 (0). Other operating income amounted to kSEK 28 (2,100). The profit after tax amounted to kSEK -9,755 (-5,178). Earnings per share before and after dillution: SEK -0.03 […]
The Board of Directors of Prolight Diagnostics AB (publ) resolves on a rights issue of units of approximately SEK 98.8 million and proposes a directed issue of shares of approximately SEK 20.9 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The […]
Prolight Diagnostics publishes half-year report, 2023
Financial overviewSecond quarter, 1 April – 30 June, Q2 2023 Group Net sales amounted to 0 (0). Other operating income amounted to kSEK 101 (2,311). The profit after tax amounted to kSEK -8,033 (-7,055). Earnings per share before and after dillution: SEK -0.03 (-0.03). Cash flow from current operations was kSEK -8,571 (-10,210). First half-year, […]
Prolight Diagnostics shows proof-of-performance for high-sensitive troponin
Prolight Diagnostics (“Prolight”) today announces that its subsidiary Psyros Diagnostics (“Psyros”) has been able to demonstrate proof-of-performance on its single molecule detection system to reproducibly detect low levels of the troponin protein. These results pave the way for early detection and rule-out of heart attack, which could reduce healthcare costs and improve the quality of […]
